INKT - MiNK Therapeutics, Inc.
IEX Last Trade
0.522
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.52
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
7.70%
1 Month
-26.93%
3 Months
-30.39%
6 Months
-40.56%
1 Year
-48.17%
2 Year
-77.10%
Key data
Stock price
$0.52
DAY RANGE
$0.52 - $0.72
52 WEEK RANGE
$0.53 - $1.90
52 WEEK CHANGE
-$51.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jennifer S. Buell
Region: US
Website: minktherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: minktherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
MiNK Therapeutics, Inc. engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate, AGENT-797, is in Phase 1 clinical trials.
Recent news